Michael Ehrgott

RadPharm is a leading imaging core lab, managing the complete imaging segment of clinical trials for the global pharmaceutical, biotechnology and medical device industries. With greater than 16 years experience supporting over 350 clinical trials, across 60 countries and 6,000 unique sites, RadPharm's vast expertise spans early stage through phase IV studies and all major therapeutic areas. In addition to having a specialty in oncology trials, they also possess deep experience with cardiovascular, musculoskeletal, CNS, diagnostic contrast imaging agents and medical device studies. RadPharm employs board-certified, sub-specialty trained radiologists, nuclear physicians and medical oncologists, uniquely positioning us to focus on the Medicine Behind the ImageTM. Its experienced medical staff interprets data from all major modalities, including, but not limited to, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), X-ray, Single Photon Emission Computed Tomography (SPECT), Ultrasound, Positron Emission Tomography (PET) and PET/CT. They provide centralized, independent, unbiased interpretation of medical images for clinical trials, integrated with a proven planning, tracking and implementation process specifically designed to exceed your expectations and timelines. RadPharm speeds delivery of your product to market by supporting your trial program with medical expertise, regulatory know-how and advanced, validated technologies. RadPharm, Inc. provides oncology and medical imaging review services. It also offers radiation therapy QA services, oncology clinical reviews, and complete medical photography services. The company was founded in 1998 by Robert Ford and is headquartered in Princeton, NJ.